“We continue to build significant momentum across our cardiac pipeline, and the recent financing strengthens our ability to execute on essential manufacturing and commercial activities for LX2006 as we look towards registrational readiness,” said R. Nolan Townsend, Chief Executive Officer of Lexeo Therapeutics (LXEO). “Interim clinical data for LX2006 demonstrate meaningful benefit across measures of cardiac health and neurologic function, including improvements in the modified Friedreich Ataxia Rating Scale, and we believe this therapy could represent a transformational step forward in the standard of care for FA. Furthermore, with enrollment complete in the HEROIC-PKP2 Phase I/II trial, we look forward to sharing new clinical data for LX2020 in January.”
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LXEO:
- Lexeo Therapeutics selloff looks ‘highly unwarranted,’ says H.C. Wainwright
- Lexeo Therapeutics Advances Study on Friedreich Ataxia-Associated Cardiomyopathy
- Lexeo Therapeutics Advances Gene Therapy Study for Genetic Heart Condition
- Lexeo Therapeutics Advances Research in Genetic Cardiomyopathy with New Study Update
- Lexeo Therapeutics Advances Gene Therapy Study for Rare Heart Condition